Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 6/20 | 0.55 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
| ▸ | HK2 | P52789 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22112295 | 0.82 | ASGR1 (0.54) | ASGR1 | |
| SCHEMBL17256336 | 0.71 | ASGR1 (1.00) | ASGR1NEU3HPSE | |
| SCHEMBL18722973 | 0.71 | ASGR1 (0.62) | ASGR1NEU3HPSE | |
| SCHEMBL26888865 | 0.70 | ASGR1 (0.64) | ASGR1HPSESMN1; SMN2 | |
| SCHEMBL26698324 | 0.70 | ASGR1 (0.64) | ASGR1HPSESMN1; SMN2 | |
| SCHEMBL25867163 | 0.70 | ASGR1 (0.64) | ASGR1HPSESMN1; SMN2 | |
| SCHEMBL7622682 | 0.70 | GAA (0.36) | ASGR1 | |
| SCHEMBL6846027 | 0.70 | GAA (0.36) | ASGR1 | |
| SCHEMBL23602763 | 0.69 | GAA (0.35) | — | |
| SCHEMBL10075955 | 0.69 | GAA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 569/4885NEU3 237/4885HPSE 395/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 385/4885NEU3 651/4885HPSE 453/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | ASGR1 437/4885NEU3 146/4885HPSE 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.